Literature DB >> 2058564

Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study).

M Galderisi1, K M Anderson, P W Wilson, D Levy.   

Abstract

Although several reports have described early changes of cardiac structure and function in diabetic patients, controversy persists regarding the existence of a clinically distinct diabetic cardiomyopathy. To this end, sex-specific linear regression analyses were used to examine the contribution of diabetes mellitus and glucose intolerance to age-adjusted echocardiographic parameters in 1,986 men (mean age 48 years) and 2,529 women (mean age 50 years) from the original Framingham Study cohort and the Framingham Offspring Study. Subjects with evidence of cardiovascular disease at the time of echocardiogram were excluded. Diabetics had higher heart rates than nondiabetics (67.9 vs 64.0 beats/min (p = 0.002) in men, and 73.1 vs 68.3 beats/min (p = 0.004) in women). Diabetic women had increased left ventricular (LV) wall thickness (18.7 vs 17.1 mm, p less than 0.001), relative wall thickness (0.403 vs 0.377, p = 0.008), LV end-diastolic dimension (46.9 vs 45.7 mm, p = 0.03) and LV mass corrected for height (100.4 vs 82.2 g/m, p less than 0.001). Women with glucose intolerance showed similar, less significant trends (p = 0.007 for wall thickness, p less than 0.01 for LV mass). In diabetic men, fractional shortening was slightly reduced (0.355 vs 0.360, p less than 0.05). In a multivariate model that included potentially confounding factors, diabetes remained an independent contributor to LV mass (p = 0.004) and wall thickness (p = 0.008) in women. In a separate linear regression model, which assessed the association of age with LV mass, the age-coefficient for diabetic women was much higher than that for nondiabetics (13.6 vs 6.6 g/m per 10-year increment in age).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 2058564     DOI: 10.1016/0002-9149(91)90716-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  118 in total

1.  LV Mass as a Predictor of CVD Events in Older Adults With and Without Metabolic Syndrome and Diabetes.

Authors:  Khiet Hoang; Yanglu Zhao; Julius M Gardin; Mercedes Carnethon; Ken Mukamal; David Yanez; Nathan D Wong
Journal:  JACC Cardiovasc Imaging       Date:  2015-08-26

2.  Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy.

Authors:  Jenie George; Alon Barsheshet; Arthur J Moss; David Martin; Gregory Ouellet; Scott McNitt; Ilan Goldenberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-01       Impact factor: 1.468

Review 3.  Type 2 diabetes, mitochondrial biology and the heart.

Authors:  Michael N Sack
Journal:  J Mol Cell Cardiol       Date:  2009-02-13       Impact factor: 5.000

4.  A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.

Authors:  G J S Cooper; A A Young; G D Gamble; C J Occleshaw; A M Dissanayake; B R Cowan; D H Brunton; J R Baker; A R J Phillips; C M Frampton; S D Poppitt; R N Doughty
Journal:  Diabetologia       Date:  2009-01-27       Impact factor: 10.122

Review 5.  The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise.

Authors:  Joel D Schilling
Journal:  Antioxid Redox Signal       Date:  2015-04-15       Impact factor: 8.401

6.  Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy.

Authors:  M Sulaiman; M J Matta; N R Sunderesan; M P Gupta; M Periasamy; M Gupta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

7.  ACE gene polymorphism and cardiac structure in patients with insulin resistance.

Authors:  Fulya Akin; Sebahat Turgut; Dursun Dursunoglu; Gunfer Turgut; Ugur Karasu; Sukru Gur
Journal:  Mol Biol Rep       Date:  2008-03-18       Impact factor: 2.316

Review 8.  Genes for left ventricular hypertrophy.

Authors:  Donna K Arnett; Lisa de las Fuentes; Ulrich Broeckel
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

9.  Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy.

Authors:  Karina Huynh; Julie R McMullen; Tracey L Julius; Joon Win Tan; Jane E Love; Nelly Cemerlang; Helen Kiriazis; Xiao-Jun Du; Rebecca H Ritchie
Journal:  Diabetes       Date:  2010-03-09       Impact factor: 9.461

10.  Association of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction.

Authors:  Anna E Hakalahti; Jari M Tapanainen; Juhani M Junttila; Kari S Kaikkonen; Heikki V Huikuri; Ulla E Petäjä-Repo
Journal:  Cardiovasc Diabetol       Date:  2010-08-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.